REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
27/04/2026
Voltar para busca
Dado oficial do USPTO
SAGASAFE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
SAGASAFE
ST13
US500000079295928Classe
5, 42, 44
Pedido
79295928
Registro
6331245
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
28/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
05/03/2020
Data de registro
27/04/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/04/2021
Última transação
28/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
SE
Examinador
SHANOSKI, JOANNA MARIE
Unidade examinadora
O30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
SAGA Diagnostics AB
Representantes
Sarah J. Schneider Sheridan Ross P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Nucleic acid sequences for medical and veterinary purposes; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing; diagnostic preparations and materialsmedical diagnostic reagents; chemical preparations for testing blood for medical purposes; chemical preparations for use in DNA analysis for medical purposes; chemical reagents for medical or veterinary purposes; chemical reagents for medical use; chemical reagents for veterinary use; chemical test reagents for medical purposes; chemical test reagents for veterinary purposes; clinical medical reagents; diagnostic agents for medical use; diagnostic biomarker reagents for medical purposes; diagnostic chemical reagents for medical use; diagnostic preparations for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic reagents for medical use; diagnostic testing materials for medical use; genetic identity tests comprised of reagents for medical purposes; in vitro diagnostic preparations for medical use; medical diagnostic reagents and assays for testing of body fluids; medical diagnostic test strips for analysis of blood and other liquids; preparations for detecting genetic predispositions for medical purposes; preparations for detecting mutation in prion genes for medical purposes; reactants for medical diagnosis being diagnostic reagents for medical purposes; reagents and media for medical and veterinary diagnostic purposes; reagents for analytical purposes for medical purposes; reagents for analytical purposes for veterinary purposes; reagents for blood grouping for medical purposes; reagents for in-vitro laboratory use for medical purposes; reagents for in-vitro laboratory use for veterinary purposes; reagents for microbiological analysis for medical purposes; reagents for microbiological analysis for veterinary purposes; reagents for use in analysis for medical purposes; reagents for use in analysis for veterinary purposes; reagents for use in diagnostic tests for medical purposes; reagents for use in diagnostic tests for veterinary purposes; reagents for use with analyzers for medical purposes; reagents for use with analyzers for veterinary purposes; reagents for use in diagnostic pregnancy tests; veterinary diagnostic reagents
Classe 42
Analysis of human serum for medical research; analysis of human tissues for medical research; biological researchclinical research in the field of cancer and infectious diseases and medical research; clinical research in the field of cancer and infectious diseases; clinical trials for others; conducting early evaluations in the field of new pharmaceuticals; consultancy relating to laboratory testing; consultancy relating to pharmaceutical research and development; medical laboratory services; medical research; medical research laboratory services; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research and development; providing information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific information in the field of medical disorders and their treatment; provision of information and data relating to medical and veterinary pharmaceutical and diagnostic research and development; research and development for the pharmaceutical industry; research and development in the pharmaceutical and biotechnology fields; scientific research and development; scientific research for medical purposes in the area of cancerous diseases; services for assessing the efficiency of pharmaceuticals; services for assessing the efficiency of veterinary drugs
Classe 44
Genetic counseling; genetic testing of animals for diagnostic or treatment purposes; laboratory analysis being medical analysis for diagnostic and treatment of persons provided by medical laboratories; medical and healthcare services; medical monitoring of patients; stem cell therapy services; medical services; analysis of human serum for medical treatment; analysis of human tissues for medical treatment; blood bank services; bowel cancer screening services; breast cancer screening services; cervical cancer screening services; colonoscopy screening services; medical consultancy and information services relating to medical products; DNA screening for medical purposes; genetic testing for medical purposes; hepatitis screening services; lung cancer screening services; medical advice in the field of pregnancy; medical analysis for the diagnosis and treatment of persons relating to cancer and infectious diseases; medical analysis services for the diagnosis of cancer; medical analysis services for cancer diagnosis and prognosis; medical analysis services for the diagnosis of cancer; medical analysis services relating to the treatment of patients relating to cancer and infectious diseases; medical analysis services relating to the treatment of persons for cancer and infectious diseases provided by a medical laboratory; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical and health services relating to DNAgenetics and genetic testing; medical care and analysis of cancer diagnosis relating to patient treatment; medical consultations; medical diagnostic services; medical evaluation services; medical analysis services for diagnostic and treatment purposes of blood samples taken from patients provided by medical laboratories; medical screening; medical services for the treatment of skin cancer; medical services in the field of oncology; medical testing for diagnostic or treatment purposes; medical testing services relating to the diagnosis and treatment of disease; prostate cancer screening services; providing cancer screening services; RNA or DNA analysis for cancer diagnosis and prognosis; services for the testing of blood; services for the testing of sera; services for the testing of urine; services for the preparation of medical reports relating to health care; technical consultancy services relating to medical health; testicular cancer screening services
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
24/07/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
15/12/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
15/12/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
15/12/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
15/12/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
15/12/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
15/12/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/01/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
29/08/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/08/2021
FIMP
FINAL DISPOSITION PROCESSED
09/08/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
27/07/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
27/04/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/02/2021
PUBO
PUBLISHED FOR OPPOSITION
09/02/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/01/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/12/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/12/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/12/2020
RFNT
REFUSAL PROCESSED BY IB
29/11/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
19/11/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
19/11/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
19/11/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
19/11/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
19/11/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
19/11/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
13/11/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/11/2020
RFRR
REFUSAL PROCESSED BY MPU
12/11/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
22/10/2020
CNRT
NON-FINAL ACTION WRITTEN
21/10/2020
MAFR
APPLICATION FILING RECEIPT MAILED
20/10/2020
DOCK
ASSIGNED TO EXAMINER
16/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
16/10/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
15/10/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SAGASAFE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.